Impact of renal artery stenting on cytokine levels, left ventricle mass and diastolic function by Rzeźnik, Daniel et al.
www.kardiologiapolska.pl
Kardiologia Polska 2013; 71, 2: 121–128; DOI: 10.5603/KP.2013.0003 ISSN 0022–9032 
ARTYKUŁ ORYGINALNY / ORIGINAL ARTICLE
Impact of renal artery stenting on cytokine levels, 
left ventricle mass and diastolic function
Daniel Rzeźnik, Tadeusz Przewłocki, Anna Kabłak-Ziembicka, Agnieszka Rosławiecka, Artur Kozanecki, 
Jacek Łach, Piotr Podolec 
Department of Cardiac and Vascular Diseases, Institute of Cardiology, Jagiellonian University School of Medicine, The Pope John Paul II  
Hospital, Krakow, Poland
A b s t r a c t
Background: Significant renal artery stenosis (RAS) may lead to left ventricle (LV) hypertrophy and diastolic function (DF) impair-
ment through complex mechanisms: activation of cytokines and/or systolic and diastolic blood pressure (SBP, DBP) increase. 
Aim: To assess interrelations between LV mass (LVM), DF and cytokines in patients undergoing renal artery stenting (PTA, 
percutaneous angioplasty of renal artery). 
Methods: The study group comprised 72 subjects (44.4% men), 64.1 ± 9.9 years with RAS referred to PTA. SBP, DBP, trans-
forming growth factor beta1 (TGF-β1), aldosterone, B-type natriuretic peptide (BNP) levels and change in LVM and LVM index 
(LVMI) and DF (Evel, e’vel, E/A ratio, E/e’ ratio, Artime-Atime) on echocardiography were assessed preprocedurally, and three and 
12 months postprocedurally. 
Results: TGF-β1 level decreased from 13.3 ± 14.9 to 8.6 ± 8.0 ng/mL (p = 0.027), while BNP increased from 89.1 ± 86.3 to 
131 ± 105 pmol/mL (p < 0.001). A significant reduction in LVMI in women (79.4 ± 16.9 vs. 95.7 ± 18.5 g/m2, p < 0.001) 
and men (77.2 ± 16.8 vs. 100.1 ± 19.7 g/m2, p < 0.001) was found at 12 months vs. baseline. Degree of LVM reduction 
correlated with baseline LVM (p < 0.001; r = –0.612) and e’vel (p = 0.05; r = 0.230), but not with BP values. Among DF 
parameters, only e’vel increased significantly at 12 months (5.54 ± 1.57 vs. 5.92 ± 1.65 cm/s; p = 0.039), while A/E and E/e’ 
ratio, Artime-Atime remained similar (p = 0.457, p = 0.283 and p = 0.258). Factors associated with e’vel increase ≥ 0.3 cm/s at 
12 months were baseline LVM < 165 g (p = 0.043, RR = 1.39, CI 1.01–1.46), Evel (p = 0.015, RR = 1.26, CI 1.15–1.52), e’vel 
(p < 0.001, RR = 1.42, CI 1.18–1.7), DBP decrease > 10 mm Hg (p = 0.055, RR = 1.2, CI 1.0–1.44) and TGF-β1 > 8 ng/mL 
(p = 0.024, RR = 1.24, CI 1.03–1.49) at 12 months. 
Conclusions. Significant LVMI reduction was observed after PTA of RAS, but it was independent of BP reduction. e’vel increase 
was independently associated with baseline LVM, Evel, e’vel, and 12 month decrease in DBP > 10 mm Hg.
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INTRODUCTION
Significant renal artery stenosis (RAS) causing renal parenchy-
mal ischaemia leads to synthesis of vasoconstrictive, trophic 
and cytotoxic molecules, such as angiotensin II, aldosterone, 
and endothelin [1]. As a consequence of neurohormone 
release, uncontrolled hypertension and left ventricle (LV) 
hypertrophy (LVH) may develop [2, 3]. LVH caused by RAS 
is thought to be the highest compared to that caused by es-
sential hypertension, or secondary to pheochromocytoma 
or hyperaldosteronism [4, 5]. There is data which suggests 
that increased level of angiotensin II prompts secretion of 
transforming growth factor beta1 (TGF-β1), and the latter 
is responsible for LV remodelling and LVH in hypertensive 
patients [6]. In response to increased angiotensin II level, el-
evated capillary wedge pressure and LV overload, also B-type 
natriuretic peptide (BNP) is released from stretched cells of 
myocardium [7]. 
Another finding usually observed in patients with RAS 
is diastolic dysfunction, which may lead as a consequence 
to diastolic heart failure, with an annual mortality rate of 8% 
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[8]. The impaired relaxation of the LV precedes the develop-
ment of LVH in hypertensive patients. On the other hand, 
LVH, impaired coronary microcirculation and neurohormo-
nal activation are common causes of progressive diastolic 
dysfunction [1]. 
In theory, renal artery angioplasty and stenting may re-
verse renal ischaemia and decrease levels of neurohormones 
and cytokines. However, there is limited data regarding the 
impact of percutaneous angioplasty of renal artery (PTA) on 
the LV mass (LVM), LVH and diastolic function (DF), as well 
as on cytokine profile [9–11]. 
Our study aimed to determine whether PTA of RAS leads 
to regression of LVH and improvement of DF, and whether 
there is an interaction with cytokine levels. 
METHODS
Seventy-two hypertensive subjects, 32 men (44.4%), 40 wom-
en (55.6%), mean age 64.1 ± 9.9 (range 43–82) years, with 
RAS were referred to PTA, including 43 (59.7%) for progres-
sive renal failure defined as progressive loss of kidney function 
over the span of time resulting in permanent kidney failure 
(estimated glomerular filtration rate — eGFR < 60 mL/min), 
two (2.7%) for pulmonary flash oedema, and 23 (31.9%) for 
arterial hypertension. At least one hypertension crisis was 
documented in 29 (40.2%) patients. RAS was recognised and 
confirmed on ultrasonography, angio-computed tomography 
or angio-magnetic resonance imaging and clinically evaluated 
in outpatient setting. Thus all subjects with a RAS diagnosis 
were admitted to the Department for the procedure.
The decision to perform PTA was reached after careful 
evaluation based on the clinical assessment, as well as an-
giographic, ultrasonographic and in some cases scintigraphic 
criteria confirming RAS severity, according to published 
guidelines for PTA of RAS [12].
All patients underwent technically successful PTA proce-
dure (defined as a residual diameter stenosis of < 30% after 
stent placement). The periprocedural and postprocedural 
management of patients undergoing PTA for RAS was in ac-
cordance with the guidelines [13, 14]. 
Coronary artery disease, if present, had to be resolved 
at least three months before PTA of RAS. Patients with car-
diovascular events during the follow-up, those who died, 
suffered from myocardial infarction or required coronary 
interventions during the first year after PTA, were not included 
into the study. 
Atherosclerosis risk factors prevalence, prior cardiovascu-
lar history: myocardial infarction, stroke, prior revascularisa-
tion procedures, as well as coronary artery disease presence 
and severity were analysed in all subjects (Table 1).
Echocardiographic examination, 24-hour ambulatory ar-
terial blood pressure monitoring (ABPM) and levels of TGF-β1, 
aldosterone and BNP were assessed in all subjects prior to 
PTA, and then three and 12 months afterwards.
Echocardiographic examination
Patients were examined in a supine position with a Toshiba 
Aplio SSA-770A echocardiographic machine (NasuWorks, 
Ottawara, Japan). All recordings were acquired with 
a multifrequency Doppler transducer placed at the cardiac 
apical window during normal respiration according to the 
guidelines of the American Society of Echocardiography 
(ASE) [13, 15]. 
LV systolic function was determined through LV ejection 
fraction by Simpson method and assessment of segmental 
contractile abnormalities with a two-dimensional echocardi-
ography from a parasternal view [15]. 
From a parasternal view, LVM and LVM index (LVMI) 
were assessed according to the ASE-recommended for-
mula: LVM = 0.8 {1.04 *[(LVIDd + IVSd + PWd)3 – 
 – (LVIDd)3]} + 0.6, where PWd and IVSd are posterior wall 
thickness at the end diastole and septal wall thickness at 
the end diastole, respectively, and LVIDd — left ventricular 
internal dimension at the end diastole.
The LVMI was obtained by normalising the LVM over 
the body surface (BSA), according to the following equation: 
LVMI [g/m2] = LVM/BSA.
Results of LVMI were analysed for women and men sepa-
rately. LVH was recognised when LVMI exceeded 95 g/m2 in 
women and 115 g/m2 in men. 
Diastolic function assessment included assessment of the 
mitral inflow (E wave and A wave velocities, A wave time, 
E/A ratio) and pulmonary vein flow (Ar time) on pulse Dop-
Table 1. Baseline characteristics of study participants
Age [years]
Male
BMI [kg/m2]
Hypertension 
Hypertension crisis
Diabetes
Hyperlipidaemia 
Current smoking
Pulmonary flash oedema
Coronary artery disease* 
CABG before PTA of RAS
PCI before PTA of RAS
eGFR [mL/min]
eGFR < 60 mL/min 
Creatinine level [µmol/L]
RAS [%]
Bilateral PTA
64.1 ± 9.9
32 (44.4%)
27.4 ± 4.97
72 (100%)
29 (40.2%)
12 (16.6%)
71 (98.6%)
27 (37.5%)
4 (5.5%)
44 (61.1%)
12 (16.6%)
23 (31.9%)
57.6 ± 24.3
43 (59.7%)
126.7 ± 56
68.4 ± 13.2
18 (25.0%)
*Presence of at least one coronary artery stenosis causing lumen 
reduction > 50%; BMI — body mass index; CABG — coronary artery 
bypass grafting; PCI — percutaneous coronary intervention; rest of 
abbreviations — see the text
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pler, as well as septal e’ mitral annulus velocity (e’vel) on tissue 
Doppler imaging (TDI). The E/e’ ratio and the difference in 
Artime-Atime were calculated.
From the apical four-chamber view, the mitral inflow (peak 
early filling E-wave velocity; Evel) and late diastolic filling A-wave 
velocity), the E/A ratio, and the isovolumetric relaxation time 
(IVRT) (derived by placing the cursor of CW Doppler in the LV 
outflow tract to simultaneously display the end of aortic ejec-
tion and the onset of mitral inflow) were assessed. Measure-
ments included mitral A-wave duration. The measurements 
were done on the 100 mm/s sweep speed at end-expiration, 
and averaged over three consecutive cardiac cycles. 
Measurements of pulmonary venous waveforms included 
peak systolic (S) velocity, peak anterograde diastolic (D) velo-
city, and the peak Ar velocity in late diastole. The duration of 
the Ar velocity was measured and the time difference between 
it and mitral A-wave duration: Artime-Atime. 
The TDI was performed in the apical views to acquire 
mitral annular velocities. The sample volume was positioned 
at or 1 cm within the septal insertion sites of the mitral leaflets 
and adjusted as necessary (5–10 mm) to cover the longitudinal 
excursion of the mitral annulus in both systole and diastole. 
Spectral recordings were obtained at a sweep speed of 50 to 
100 mm/s at end-expiration and those measurements re-
flected the average of ≥ 3 consecutive cardiac cycles. Velocity 
of the early diastolic myocardial motion (e’vel) was measured. 
The E/e’ ratio was calculated. 
The assessment of the grade of diastolic dysfunction was 
performed according to ASE guidelines. In brief, normal DF 
was assumed when septal e’vel exceeded 8 cm/s. Diastolic 
dysfunction was recognised when septal e’vel was less than 
8 cm/s. The diastolic dysfunction was distinguished into three 
grades [13]: 
 — In (Grade I), the parameters were E/A < 0.8, E/e’ ≤ 8 
and Artime-Atime < 0 ms. 
 — In (Grade II) the parameters were E/A 0.8–1.5, E/e’ 9–12 
and Artime-Atime > 30 ms.
 — In (Grade III) the parameters were E/A > 2.0, E/e’ ≥ 13 
and Artime-Atime > 30 ms. 
An Artime-Atime velocity duration > 30 ms was assumed 
a marker of an elevated LV end-diastolic pressure. The septal 
E/e’ ratio of < 8 was assumed as associated with normal LV 
filling pressures, whereas a ratio > 15 was associated with 
increased filling pressures. 
Renal function
This was evaluated by eGFR measured using the Cock-
roft-Gault formula:
 — for men: eGFR = [140 – age) × body weight]/[serum 
creatinine concentration (mg/dL) × 72]
 — for women: eGFR = [140 – age) × body weight]/[serum 
creatinine concentration (mg/dL) × 72] × 0.85
The results were expressed in mL/min.
Cytokine and hormone level assessment
Blood for serum and EDTA plasma was taken before, and three 
and 12 months after, the PTA procedure. Aldosterone con-
centration was determined by radioimmunometric method 
(CISbio, France). TGF-β1 was measured by immunoenzymatic 
method (R&D, USA), and BNP by chemiluminescent method 
(Siemens, USA). The intra- and interassay coefficients of varia-
tion were as follows: aldosterone 8% and 6%, TGF-β1 2.5% 
and 8%, BNP 2% and 2.1%, respectively.
Blood pressure assessment
Blood pressure was assessed with 24-hour ABPM prior to the 
PTA procedure, then at three and 12 months afterwards. The 
mean systolic and diastolic BP (SBP, DBP), as well as SBP and 
DBP loads, were assessed and analysed. 
The blood lowering medications were noted and analysed 
with regard to their number and doses prior to PTA and afterwards. 
The mean baseline number of the blood lowering 
medications was 3.2 ± 1.1 (range 1–7), including angiotensin 
converting enzyme inhibitors (ACEI) in 41 (56.9%), sartans 
in five (6.9%), beta-blockers in 56 (77.7%), calcium channel 
blockers in 40 (55.5%), diuretics in 51 (70.8%), alpha-blockers 
in 11 (15.2%) and imidazol receptor blockers in 14 (19.4%) 
subjects. Twelve subjects had at least two or more medical 
regimens from the same pharmacological group (e.g. two 
diuretics: indapamid and torasemid). 
The study protocol was reviewed and approved by the lo-
cal Ethics Committee and all patients signed informed consent.
Analysis
Categorical variables are reported as frequencies and percent-
ages; continuous variables, as mean ± SD. Student’s t tests or 
Wilcoxon’s two-sample tests were used to compare continuous 
variables; χ2 tests were used to compare categorical variables. 
Bivariate correlation analysis was performed with Pear-
son’s or coefficients to investigate whether change in LVM and 
DF parameters was correlated with hypertension improve-
ment or cytokine level.
The factors associated with improvement in septal e’vel 
or LVM reduction were initially sought with univariate analy-
sis. Then, variables that were associated with e’vel or LVM 
reduction at p-level < 0.1 were introduced to multivariate 
step-wise backward logistic regression analysis, preferably as 
categorical variables, whenever possible. The cut-off values 
for significant variables were established empirically. For those 
variables, a relative risk (RR) and 95% confidence intervals 
(95% CI) were calculated. 
Differences at the level of p < 0.05 (two-tailed) were 
considered statistically significant.
RESULTS
In the whole study group, the mean SBP decreased by 6.5 mm 
Hg and mean DBP by 2.4 mm Hg; also SBP and DBP loads 
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decreased significantly (Table 2). The mean number of blood 
lowering medications was reduced from 3.2 ± 1.1 (range 1–7) 
at baseline to 2.9 ± 1.1 at 12 months after PTA (Table 2). 
However, ACEI and sartans were not withdrawn in patients.
The mean TGF-β1 level decreased from 13.3 ± 14.9 to 
8.6 ± 8.0 ng/mL (p = 0.027), while aldosterone level did 
not change significantly (208 ± 240 pg/mL prior to PTA 
and 175 ± 134 pg/mL at 12 months after PTA; p = 0.139). 
Surprisingly, mean BNP level increased significantly from 
89.1 ± 86.3 to 131 ± 105 pmol/mL (p < 0.001; Table 2). 
Baseline BNP level was primarily correlated with baseline 
LV ejection fraction (p = 0.011, r = –0.297), and the same 
was noted at 12 months (p < 0.001, r = –0.454). BNP level 
decreased in 30 (41.7%), and increased in 42 (58.3%) sub-
jects after PTA.
In patients in whom BNP concentration decreased after PTA, 
higher grade of RAS (73 ± 13.9 vs. 65.1 ± 11.8%, p = 0.012), 
more often bilateral RAS (53 vs. 21%, p = 0.005), higher base-
line creatinine level (143 ± 70 vs. 115 ± 41 µmol/L, p = 0.04), 
lower eGFR (50.4 ± 20 vs. 63 ± 26 mL/min, p = 0.034), and 
lower DBP load at 12 months (16.1 ± 12 vs. 26.1 ± 22%, 
p = 0.028) were noted compared to patients in whom BNP 
Table 2. Left ventricular mass, left ventricular mass index, left ventricular systolic and diastolic function on echocardiography, 
cytokine levels and blood pressure parameters initially and three and 12 months after PTA of RAS
Baseline 3 months 12 months P (12 months vs. baseline)
Creatinine level [µmol/L]
No of BP lowering regimens
Systolic BP [mm Hg]
Systolic BP load [%]
Diastolic BP [mm Hg]
Diastolic BP load [%]
126.7 ± 56
3.2 ± 1.1
134.9 ± 19
45.8 ± 29
75.3 ± 11
28.7 ± 24
115.1 ± 62
2.93 ± 1.3
130.4 ± 14
41.3 ± 25
74.2 ± 8.8
22.1 ± 18
117.0 ± 52
2.9 ± 1.2
128.4 ± 13
37.8 ± 24
72.9 ± 9.1
22.0 ± 19
0.081
0.030
0.002
0.031
0.034
0.011
Cytokines level
TGF-β [ng/mL]
BNP [pg/mL]
Aldosterone [pg/mL]
13.3 ± 14.9
89.1 ± 86.3
207.9 ± 240
9.4 ± 9.4
99 ± 121
198 ± 250
8.6 ± 8.0
131 ± 105
175 ± 134
0.027
< 0.001
0.393
LV systolic function
LV ejection fraction [%] 60.0 ± 10.1 60.7 ± 10.1 59.2 ± 10.6 0.547
LVM, LVMI 
LVM [g]
LVMI in women [g/m2]
LVMI in men [g/m2]
IVSd [mm]
IVSs [mm]
178 ± 42
96.8 ± 18
101.7 ± 21
12.1 ± 2.6
17.1± 3.0
164.1 ± 38
89.5 ± 17.7
91.2 ± 22.8
10.7 ± 2.1
15.7 ± 2.7
147.7 ± 34.7
81.7 ± 17
81.4± 18.8
10.4 ± 1.7
14.6 ± 2.4
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
LV diastolic function
No diastolic dysfunction
Grade I
Grade II
Grade III
LV diastolic function parameters
Evel [cm/s]
E/A ratio
IVRT [ms]
E’vel [cm/s]
E/e’ ratio
A velocity [cm/s]
A time [ms]
Ar time [ms]
Artime-Atime [ms]
4 (5.5%)
2 (2.7%)
25 (34.7%)
41 (56.9%)
83.8 ± 25
1.01 ± 0.39
115.0 ± 26
5.54 ± 1.57
16.6 ± 7.1
87.6 ± 22.7
164.6 ± 49
143.8 ± 34.9 
–23.3 ± 57.5
8 (11.1%)
3 (4.2%)
22 (30.5%)
39 (54.1%)
82.3 ± 21.4
1.03 0.46
114.8 ± 26
5.83 ± 1.57
16.1 ± 8.1
86.5 ± 23.7
163.0 ± 44
139.1 ± 31 
–23.5 ± 49.4
10 (13.8%)
2 (2.7%)
21(29.2%)
39 (54.1%)
80.3 ± 24.8
0.98 ± 0.34
113.2 ± 24
5.92 ± 1.65
15.4 ± 7.6
83.3 ± 24.7
169.2 ± 47
137.7 ± 26 
–34.9 ± 49
0.091
0.281
0.457
0.644
0.039
0.283
0.157
0.468
0.389
0.468
Abbreviations — see the text
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level increased. Also, greater degrees of SBP, DBP, SBP load 
and DBP load reductions were observed, although they did 
not reach statistical significance (–10.5 ± 20 vs. –3.4 ± 15 mm 
Hg, p = 0.093; –3.3 ± 10 vs. –31.6 ± 9 mm Hg, p = 0.446, 
–15.1 ± 33 vs. –1.9 ± 31, p = 0.091; –11.4 ± 22 vs. –3 ± 20 mm 
Hg, p = –0.099, respectively). However, the independent fac-
tors associated with BNP level reduction following PTA were: 
degree of RAS (p = 0.012, RR = 1.33, CI 1.07–1.65) and DBP 
load at 12 months (p = 0.028, RR = 0.78, CI 0.63–0.97).
LVH was recognised in 17 (42.5%) out of 40 women and 
nine (28.1%) out of 32 men before PTA, and in 15 (37.5%) 
and five (15.6%) at three months, and in seven (17.5%) and 
two (6.2%) at 12 months after PTA (p = 0.015 for women, and 
p = 0.02 for men at 12 months vs. baseline). The mean LVM 
reduction was –30.5 ± 33.6 g (range from –101 g to + 37 g) 
at 12 months vs. baseline (p < 0.001). Baseline LVM was cor-
related with initial BNP level (p = 0.006, r = 0.295), but not 
with aldosterone (p = 0.191, r = 0,164) or TGF-β1 (p = 0.251, 
r = –0.123). 
In women, LVMI decreased from initial 95.7 ± 18.5 to 
79.4 ± 16.9 g/m2 (p < 0.001) at 12 months after PTA, while 
in men from 100.1 ± 19.7 to 77.2 ± 16.8 g/m2 (p < 0.001), 
respectively (Table 2). Degree of LVM reduction correlated 
with baseline LVM (p < 0.001, r = –0.612), IVSs (p < 0.001, 
r = –0.520), IVSd (p < 0.001, r = –0.453) and e’vel (p = 0.052, 
r = 0.230; Table 3). There was no correlation between the 
degree of LVM reduction, cytokine levels and initial or final 
BP values, nor between degree of LVM reduction and the 
degree of change in mean SBP, DBP, or loads of SBP and 
DBP at 12 months (Table 3). In subjects in whom a significant 
LVM reduction was observed, thicker baseline IVSd, IVSs and 
higher baseline LVM as well as higher baseline SBP and SBP 
load, SBP and SBP load at 12 months, but lower baseline e’vel 
and e’vel at 12 months, were noted. Among these factors, the 
identified factors independently associated with LVM reduc-
tion of at least 30 g at 12 months vs. baseline were: high 
baseline LVM exceeding 190 g and IVSs thickness exceeding 
18 mm (Table 4).
The LV systolic function remained similar at baseline, 
at three and at 12 months after PTA (LV ejection fraction: 
60.0 ± 10.1 vs. 60.7 ± 10.1 vs. 59.2 ± 10.6; p = 0.547, 
respectively, Table 2). 
Normal DF was observed initially in four (5.5%) out 
of 72 patients, and the number of patients with normal 
DF increased to ten (13.8%) after 12 months of follow-up 
(p = 0.091), while in the remaining 62 (86.2%) patients 
diastolic dysfunction persisted (Table 2).
In the whole study group, among DF parameters, 
only mean septal e’vel increased significantly at 12 months 
(5.54 ± 1.57 vs. 5.92 ± 1.65 cm/s, p = 0.039), while mean A/E 
and E/e’ ratio, mean Artime-Atime remained similar (p = 0.457, 
p = 0.283 and p = 0.258, Table 2). In subjects in whom 
e’vel increase ≥ 0.3 cm/s at 12 months was observed, lower 
baseline LVM, septal e’vel, E/A ratio, baseline and 12 month 
BNP level, as well as higher degree of SBP and DBP reduc-
tion after PTA. Among these factors, the independent ones 
associated with septal e’vel increase ≥ 0.3 cm/s at 12 months 
after PTA were baseline LVM < 165 g (p = 0.043, RR = 1.21, 
CI 1.01–1.46), low baseline Evel ≤ 90 cm/s (p = 0.015, 
RR = 1.26, CI 1.05–1.52), baseline septal e’vel ≤ 5.5 cm/s 
(p < 0.001, RR = 1.42, CI 1.18–1.7) and decrease in 
Table 3. Spearman’s co-efficient correlations between degree 
of left ventricular mass change, E/e’, septal e’vel and blood 
pressure values
Correlations between the degree 
of LVM reduction at 12 months 
vs. baseline
Spearman 
R
P
Echocardiographic parameters
Baseline LVM
Baseline IVSd
Baseline IVSs 
Baseline e’vel
e’vel at 12 months
E/e’ ratio at 12 months
–0.612
–0.453
–0.520
0.230
0.247
–0.229
< 0.001
< 0.001
< 0.001
0.052
0.037
0.065
Blood pressure values
Baseline SBP
Baseline DBP
Baseline SBP load
Baseline DBP load
SBP at 12 months
DBP at 12 months
SBP load at 12 months
DBP load at 12 months
Change in SBP at 12 months vs. baseline
Change in DBP at 12 months vs. baseline
Change in SBP load at 12 months 
vs. baseline
Change in DBP load at 12 months 
vs. baseline
–0.216
–0.176
–0.201
–0.138
–0.200
–0.114
–0.193
–0.114
0.102
0.118
0.096
 
0.147
0.068
0.139
0.095
0.255
0.092
0.340
0.105
0.340
0.396
0.325
0.425
 
0.218
Cytokines level
Baseline TGF-β
TGF-β at 12 months
Change in TGF-β at 12 months  
vs. baseline
Baseline BNP
BNP at 12 months
Change in BNP at 12 months vs. baseline
Baseline aldosterone
Aldosterone at 12 months
Change in aldosterone at 12 months 
vs. baseline
0.117
0.199
0.066
 
–0.185
–0.206
–0.138
–0.068
–0.104
–0.021
0.330
0.120
0.582
 
0.122
0.121
0.260
0.611
0.436
0.866
Abbreviations — see the text
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DBP > 10 mm Hg at 12 months vs. baseline (p = 0.055, 
RR = 1.2, CI 1.0–1.44) and TGF-β1 > 8 ng/mL (p = 0.024, 
RR = 1.24, CI 1.03–1.49) at 12 months (Table 4). High BNP 
level > 120 pg/mL at 12 months was a predictor of a lack of 
e’vel increase (p = 0.004, RR = 0.75, CI 0.62–0.91) (Table 4).
DISCUSSION 
In patients with diagnosed RAS, the need for renal artery re-
vascularisation is debated, as the clinical outcome in terms of 
renal function and BP control are disappointing, as reported 
by large multicentre randomised trials [14, 16]. On the other 
hand, significant RAS is often encountered in patients with 
atherosclerotic stenoses in other arterial beds, e.g. coronary 
or carotid arteries [17, 18]. In such patients, especially, when 
there is evidence of poorly controlled hypertension or pro-
gressive renal failure, PTA of RAS is tempting. To date, the 
other potential benefits of PTA for RAS, such as LVH reduc-
tion or diastolic function improvement, have not been widely 
studied [9–11]. 
Although only about 35% of our patients in the present 
study had LVH, the important finding is that the evident LVM 
reduction during one year following PTA of RAS was observed. 
The degree of LVM reduction was independently related to 
the initial LVM and septal wall thickness at systole. The septal 
wall thickness exceeding 18 mm at systole before PTA might 
be a clinically relevant marker of favourable outcome in terms 
of LVM reduction. IVSs is also a parameter easier to measure 
and more reproducible than LVM assessment. In the studies 
by Symonides et al. [19] and Zeller et al. [20], the degree of 
LVM and LVMI reduction correlated positively with a higher 
baseline LVM, LVMI, and IVS thickness. 
In our study, LVM reduction was not associated with 
reduced BP values, similarly to Zeller et al. [20], who neither 
observed a correlation between the degree of LVM or LVMI 
change and BP values. In these two studies, SBP and DBP 
reduction after PTA were rather mild (in our study by 6.5 and 
2.4 mm Hg, respectively) but a significant reduction in the 
number of blood lowering medications in both studies was ob-
served [20]. On the contrary, in studies in which LVM reduction 
correlated well with degree of BP lowering, the degree of BP 
reduction was much greater [19, 21]. In Symonides et al. [19], 
SBP and DBP were reduced by 20 mm Hg and 12 mm Hg, 
respectively. Yoshitomi et al. [21] observed that lowering of 
mean BP by 25 mm Hg was significantly correlated and LVMI 
reduction (r = 0.77, p < 0.01) in patients with unilateral RAS.
On the other hand, the reduction in BP values correlated 
significantly with TDI septal e’vel in our present study. Low-
ering of DBP ≥ 10 mm Hg was an independent prognostic 
marker of DF improvement, in particular of TDI e’vel increase. 
The other independent factors associated with e’vel increase 
over 0.3 cm/s at 12 months vs. baseline were: low baseline 
LVM < 165 g, initial e’vel ≤ 5.5 cm/s and Evel ≤ 90 cm/s, as well 
as TGF-β1 concentration > 8 ng/mL 12 months after PTA of 
RAS. BNP level > 120 pg/mL at 12 months was an important 
marker indicating lack of DF improvement following PTA. 
Kawarada et al. [22] also reported significant e’vel in-
crease after PTA and observed decrease in E/e’ ratio related 
to DF improvement. This finding contrasts with the study of 
Corriere et al. [9], who did not observe a significant change 
in E/e’ ratio or recovery from diastolic dysfunction during 
follow-up. A possible explanation for these conflicting find-
ings is the differences in patient characteristics. In our current 
study and the study of Kawarada et al. [22], more patients 
had concomitant coronary, carotid and/or peripheral artery 
disease, diabetes or underwent revascularisation procedures, 
compared to the Corriere et al. study [9, 22, 23]. Furthermore, 
normal DF was observed in only 5.5% of our subjects, but 
in 25% in the Corriere et al. study [9]. In our present study, 
there was a trend to significance with regard to patients in 
whom DF normalised after PTA of RAS (13.8%), while there 
was evident improvement in NYHA functional class in the 
Kawarada et al. study [22].
Table 4. Multivariate stepwise backward logistic regression analysis. Predictors of left ventricular mass decrease by at least 30 g and 
septal e’vel increase by at least 0.3 cm/s at 12 months after PTA of RAS, compared to initial respective values
Relative risk 95% confidence interval P
LVM decrease ≥ 30 g
Baseline LVM ≥ 190 g
Baseline IVSs ≥ 18 mm
1.29
1.48
1.03–1.60
1.19–1.84
0.027
0.001
Septal e’vel increase ≥ 0.3 cm/s
Baseline LVM < 165 g
Baseline Evel ≤ 90 cm/s
Baseline septal e’vel ≤ 5.5 cm/s
Decrease in DBP > 11 mm Hg (12 months vs. baseline)
TGF-β > 8 ng/mL at 12 months
BNP > 120 pg/mL at 12 months
1.21
1.26
1.42
1.20
1.24
0.75
1.01–1.46
1.05–1.52
1.18–1.70
1.00–1.44
1.03–1.49
0.62–0.91
0.043
0.015
< 0.001
0.055
0.024
0.004
Abbreviations — see the text
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We did not find any correlations between LVM and 
cytokines, with the only exception being baseline LVM and 
initial BNP level (p = 0.006, r = 0.295). The later finding is in 
line with observations that plasma BNP might be a marker of 
LVH in hypertensive subjects, inducing suppression of plasma 
aldosterone. Almendral et al. [24] observed a significant cor-
relation between LVM and TGF-β1 level.
Interestingly, in our study, mean TGF-β1 level decreased sig-
nificantly after PTA, although this reduction was not correlated 
with the degree of LVM reduction. The TGF-β1 level reduction 
is thought to reflect decrease in renal injury and improved 
renoprotection through the antisclerotic effects [24]. However, 
there is no data in literature about associations between PTA of 
RAS and TGF-β1. We might try to extrapolate results of Laviades 
et al. [25], who showed that responders to angiotensin II block-
ers therapy have significantly lower TGF-β1 concentration than 
nonresponders [25]. It is possible that PTA leads to angiotensin 
II level reduction, which leads to decrease of TGF-β1 level. 
There is no clear explanation for the increase of BNP 
level after PTA in the current study. As patients with recent 
cardiovascular events, including myocardial infarction, were 
not included into this study, it seems reasonable that change 
in BNP level should reflect the beneficial effect of PTA on LVM 
reduction, DF improvement and BP values. Our results are in 
contrast to the studies of Silva et al. [7] and Rastan et al. [11], 
that showed a significant reduction of plasma BNP concentra-
tion after PTA, and an even greater BP decrease in those who 
had higher baseline BNP level. In our present study, in patients 
with BNP level reduction after PTA, a higher degree of RAS, 
bilateral PTA, more impaired renal function and higher degree 
of BP reduction were observed.  
CONCLUSIONS
PTA of RAS induces mild, though significant, BP reduction. 
Significant reductions of LVM and LVMI were observed in 
patients treated with PTA, but this was independent to the 
degree of BP and cytokine level reductions. A significant dia-
stolic function improvement was seen only in a minority of 
subjects, although it was associated with DBP reduction and 
cytokine levels. The LVM reduction mechanisms following 
PTA of RAS need further investigation. 
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Wpływ angioplastyki tętnic nerkowych  
na stężenie cytokin, masę i funkcję rozkurczową 
lewej komory
Daniel Rzeźnik, Tadeusz Przewłocki, Anna Kabłak-Ziembicka, Agnieszka Rosławiecka, Artur Kozanecki, 
Jacek Łach, Piotr Podolec 
Klinika Chorób Serca i Naczyń, Instytut Kardiologii, Collegium Medicum, Uniwersytet Jagielloński, Szpital im. Jana Pawła II, Kraków 
S t r e s z c z e n i e
Wstęp: Istotne zwężenie tętnic nerkowych (RAS), powodując wzrost stężenia cytokin oraz wartości skurczowego i rozkur-
czowego ciśnienia tętniczego (SBP, DBP), może prowadzić do przerostu mięśnia lewej komory (LV) i upośledzenia funkcji 
rozkurczowej (DF) miokardium.
Cel: Celem badania była ocena wzajemnych zależności między masą LV (LVM), DF i stężeniem cytokin u chorych poddawa-
nych stentowaniu tętnic nerkowych (PTA).
Metody: Do badania włączono 72 chorych (44,4% mężczyzn) w średnim wieku 64,1 ± 9,9 roku, z RAS po zabiegu PTA. 
U wszystkich chorych określano SBP, DBP, stężenia transformującego czynnika wzrostu beta1 (TGF-β1), aldosteronu, peptydu 
natriuretycznego (BNP), zmiany LVM i wskaźnika masy lewej komory (LVMI), a także echokardiograficzne parametry DF, 
tj. (Evel, e’vel, współczynnik E/A, współczynnik E/e’, Artime-Atime) przed, 3 i 12 miesięcy po PTA. 
Wyniki: Po zabiegu zaobserwowano zmniejszenie stężenia TGF-β1 z 13,3 ± 14.9 do 8,6 ± 8,0 ng/ml (p = 0,027), natomiast 
wzrost BNP z 89,1 ± 86,3 do 131 ± 105 pmol/ml (p < 0,001). W 12 miesięcy po zabiegu stwierdzono znamienny spadek 
LVMI zarówno u kobiet (79,4 ± 16,9 vs. 95,7 ± 18,5 g/m2, p < 0,001), jak i u mężczyzn (77,2 ± 16,8 vs. 100,1 ± 19,7 g/m2, 
p < 0,001) w porównaniu z wartościami sprzed PTA. Stopień redukcji LVM korelował z wyjściową LVM (p < 0,001; r = –0,612) 
i prędkością e’vel (p = 0,05; r = 0,230), natomiast nie korelował z parametrami BP. Wśród parametrów DF zaobserwowano 
istotne zwiększenie prędkości e’vel 12 miesięcy po PTA (5,54 ± 1,57 vs. 5,92 ± 1,65 cm/s; p = 0,039), natomiast współczyn-
niki: A/E, E/e’, Artime-Atime nie zmieniły się istotnie (p = 0,457; p = 0,283; p = 0,258). Czynnikami związanymi ze wzrostem 
prędkości e’vel ≥ 0,3cm/s 12 miesięcy po PTA były: LVM < 165 g (p = 0,043; RR = 1,39; CI 1,01–1,46), Evel (p = 0,015; 
RR = 1,26; CI 1,15–1,52) oraz e’vel (p < 0,001; RR = 1,42; CI 1,18–1,7) przed zabiegiem, a także zmniejszenie DBP o co 
najmniej 10 mm Hg (p = 0,055; RR = 1,2; CI 1,0–1,44) i stężenie TGF-β1 > 8 ng/ml (p = 0,024; RR = 1,24; CI 1,03–1,49) 
12 miesięcy po PTA. 
Wnioski: W rocznej obserwacji u chorych poddanych PTA w przebiegu RAS obserwuje się znamienną redukcję LVMI, która 
jednak jest niezależna od stopnia redukcji BP. Wzrost prędkości e’vel jest niezależnie związany z początkową LVM, Evel, i  e’vel 
oraz spadkiem DBP o co najmniej 10 mm Hg 12 miesięcy po PTA.
Słowa kluczowe: zwężenie tętnic nerkowych, ciśnienie skurczowe i rozkurczowe, lewa komora, funkcja rozkurczowa, 
wskaźnik masy lewej komory, stentowanie tętnic nerkowych, transformujący czynnik wzrostu beta1, peptyd natriuretyczny 
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